vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and HCI Group, Inc. (HCI). Click either name above to swap in a different company.
HCI Group, Inc. is the larger business by last-quarter revenue ($246.2M vs $168.4M, roughly 1.5× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 52.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 9.2%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
HCI Equity Partners is a Washington, DC–based private equity firm with an additional office in Chicago, Illinois.
ESPR vs HCI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $246.2M |
| Net Profit | — | $97.7M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 58.5% |
| Net Margin | — | 39.7% |
| Revenue YoY | 143.7% | 52.1% |
| Net Profit YoY | — | 3679.2% |
| EPS (diluted) | $0.32 | $7.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $246.2M | ||
| Q3 25 | $87.3M | $216.3M | ||
| Q2 25 | $82.4M | $221.9M | ||
| Q1 25 | $65.0M | $216.4M | ||
| Q4 24 | $69.1M | $161.9M | ||
| Q3 24 | $51.6M | $175.3M | ||
| Q2 24 | $73.8M | $206.2M | ||
| Q1 24 | $137.7M | $206.6M |
| Q4 25 | — | $97.7M | ||
| Q3 25 | $-31.3M | $65.5M | ||
| Q2 25 | $-12.7M | $66.2M | ||
| Q1 25 | $-40.5M | $69.7M | ||
| Q4 24 | — | $2.6M | ||
| Q3 24 | $-29.5M | $5.7M | ||
| Q2 24 | $-61.9M | $54.1M | ||
| Q1 24 | $61.0M | $47.6M |
| Q4 25 | 50.6% | 58.5% | ||
| Q3 25 | -11.4% | 41.9% | ||
| Q2 25 | 8.6% | 42.5% | ||
| Q1 25 | -34.0% | 46.4% | ||
| Q4 24 | -6.4% | 3.6% | ||
| Q3 24 | -31.0% | 8.0% | ||
| Q2 24 | 3.5% | 36.9% | ||
| Q1 24 | 52.5% | 37.5% |
| Q4 25 | — | 39.7% | ||
| Q3 25 | -35.9% | 30.3% | ||
| Q2 25 | -15.4% | 29.8% | ||
| Q1 25 | -62.2% | 32.2% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | -57.2% | 3.2% | ||
| Q2 24 | -83.9% | 26.2% | ||
| Q1 24 | 44.3% | 23.0% |
| Q4 25 | $0.32 | $7.29 | ||
| Q3 25 | $-0.16 | $4.90 | ||
| Q2 25 | $-0.06 | $5.18 | ||
| Q1 25 | $-0.21 | $5.35 | ||
| Q4 24 | $-0.14 | $0.32 | ||
| Q3 24 | $-0.15 | $0.52 | ||
| Q2 24 | $-0.33 | $4.24 | ||
| Q1 24 | $0.34 | $3.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $1.2B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $1.0B |
| Total Assets | $465.9M | $2.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $1.2B | ||
| Q3 25 | $92.4M | $987.9M | ||
| Q2 25 | $86.1M | $947.2M | ||
| Q1 25 | $114.6M | $754.5M | ||
| Q4 24 | $144.8M | $532.5M | ||
| Q3 24 | $144.7M | $518.8M | ||
| Q2 24 | $189.3M | $445.8M | ||
| Q1 24 | $226.6M | $655.4M |
| Q4 25 | $-302.0M | $1.0B | ||
| Q3 25 | $-451.4M | $821.8M | ||
| Q2 25 | $-433.5M | $758.6M | ||
| Q1 25 | $-426.2M | $522.7M | ||
| Q4 24 | $-388.7M | $453.3M | ||
| Q3 24 | $-370.2M | $455.3M | ||
| Q2 24 | $-344.2M | $447.3M | ||
| Q1 24 | $-294.3M | $395.7M |
| Q4 25 | $465.9M | $2.5B | ||
| Q3 25 | $364.0M | $2.3B | ||
| Q2 25 | $347.1M | $2.4B | ||
| Q1 25 | $324.0M | $2.3B | ||
| Q4 24 | $343.8M | $2.2B | ||
| Q3 24 | $314.1M | $2.0B | ||
| Q2 24 | $352.3M | $1.9B | ||
| Q1 24 | $373.1M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $444.4M |
| Free Cash FlowOCF − Capex | — | $440.8M |
| FCF MarginFCF / Revenue | — | 179.0% |
| Capex IntensityCapex / Revenue | 0.0% | 1.5% |
| Cash ConversionOCF / Net Profit | — | 4.55× |
| TTM Free Cash FlowTrailing 4 quarters | — | $771.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $444.4M | ||
| Q3 25 | $-4.3M | $26.7M | ||
| Q2 25 | $-31.4M | $145.0M | ||
| Q1 25 | $-22.6M | $162.0M | ||
| Q4 24 | $-35.0M | $331.8M | ||
| Q3 24 | $-35.3M | $104.1M | ||
| Q2 24 | $-7.2M | $-29.0M | ||
| Q1 24 | $53.8M | $182.0M |
| Q4 25 | — | $440.8M | ||
| Q3 25 | — | $25.9M | ||
| Q2 25 | — | $144.5M | ||
| Q1 25 | — | $160.3M | ||
| Q4 24 | — | $327.8M | ||
| Q3 24 | $-35.5M | $103.2M | ||
| Q2 24 | $-7.3M | $-30.1M | ||
| Q1 24 | $53.8M | $181.0M |
| Q4 25 | — | 179.0% | ||
| Q3 25 | — | 12.0% | ||
| Q2 25 | — | 65.1% | ||
| Q1 25 | — | 74.1% | ||
| Q4 24 | — | 202.5% | ||
| Q3 24 | -68.7% | 58.9% | ||
| Q2 24 | -9.9% | -14.6% | ||
| Q1 24 | 39.0% | 87.6% |
| Q4 25 | 0.0% | 1.5% | ||
| Q3 25 | 0.0% | 0.4% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.0% | 2.5% | ||
| Q3 24 | 0.3% | 0.5% | ||
| Q2 24 | 0.1% | 0.5% | ||
| Q1 24 | 0.1% | 0.5% |
| Q4 25 | — | 4.55× | ||
| Q3 25 | — | 0.41× | ||
| Q2 25 | — | 2.19× | ||
| Q1 25 | — | 2.32× | ||
| Q4 24 | — | 128.41× | ||
| Q3 24 | — | 18.33× | ||
| Q2 24 | — | -0.54× | ||
| Q1 24 | 0.88× | 3.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
HCI
| Insurance Operation | $218.3M | 89% |
| Reciprocal Exchange Operation | $27.0M | 11% |
